Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis-Reference-Cited by-同舟云学术

Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis

Published:2018-02-28 Issue:2 Volume:13 Page:205-216
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Schmidt Elvira^ORCID,Lister Johanna,Neumann Monika,Wiecek Witold,Fu Shuai,Vataire Anne-Lise,Sostar Jelena,Huang Shengnan,Marteau Florence

Funder

Ipsen Pharma SAS

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s11523-018-0559-0/fulltext.html

Reference53 articles.

1. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24. https://doi.org/10.1016/j.eururo.2015.01.005 .

2. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008;14(5):288–301. https://doi.org/10.1097/PPO.0b013e3181867628 .

3. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–30. https://doi.org/10.1016/j.eururo.2014.10.002 .

4. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205. https://doi.org/10.1016/j.ctrv.2007.12.001 .

5. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9. https://doi.org/10.1200/JCO.2008.21.4809 .

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project;Cancers;2024-08-28

2. Case report: treatment of metastatic renal cell carcinoma with nivolumab plus cabozantinib in routine clinical practice;Malignant tumours;2022-07-07

3. ANALYSIS OF THE EFFECT OF PERIOPERATIVE NURSING IN PATIENTS WITH T1-STAGE RENAL CANCER UNDERGOING 3D LAPAROSCOPIC PARTIAL NEPHRECTOMY;ACTA MEDICA MEDITERR;2022

4. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma;European Urology;2021-12

5. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma;New England Journal of Medicine;2021-03-04